Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done
Nowadays, the retreatment of patients with Hepatitis C virus (HCV) genotype 3 (GT3) especially cirrhotic, who have already been treated with regimens containing a NS5A inhibitor represents a challenge. Use a novel retreatment option for patients with a difficult approach. We present three case repor...
Main Authors: | Susana Llerena, Joaquín Cabezas, Antonio Cuadrado, José Manuel Olmos, Marta González, Federico García, Carmen Cobo, Javier Crespo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-01-01
|
Series: | Annals of Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119303291 |
Similar Items
-
Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection
by: Hussien Ahmed, et al.
Published: (2018-01-01) -
Eradication of hepatitits C virus in patient with cryoglobulinemic vasculitis and mutations D168E, L31V
by: N. V. Dunaeva, et al.
Published: (2020-03-01) -
Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient
by: Jin Chen, et al.
Published: (2020-01-01) -
Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
by: Eun Sun Jang, et al.
Published: (2021-03-01) -
A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
by: Li H, et al.
Published: (2020-02-01)